

SEP 10 2008

PATENT

Rev 02/07

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : Laszlo Takacs et al.
Application No. : 10/588,392
Filed : August 03, 2006
Confirmation No. : 8285
For : MONOCLONAL ANTIBODY BASED BIOMARKER
DISCOVERY AND DEVELOPMENT PLATFORM
Examiner : Jeffrey S. Lundgren
Attorney's Docket : NU-BI-659XX

TC Art Unit: 1639

I hereby certify that this correspondence is being sent via
facsimile to Examiner Jeffrey S. Lundgren, TC Art Unit 1639, Fax
No. (571) 273 8300, on Sept. 10, 2008.

By: Holliday C. Heine
Holliday C. Heine, Ph.D.
Registration No. 34,346
Attorney for Applicant(s)

RESPONSE TO RESTRICTION REQUIREMENT

Via Facsimile
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Restriction Requirement dated August 11,
2008, Applicants hereby elect Group I, with traverse, for
prosecution at this time. The species elected for search purposes
are:

Attorney Docket No. NU-BI-659XX
WEINGARTEN, SCHURGIN,
GAGNEBIN & LEBOVICI LLP
TEL. (617) 542-2290
FAX. (617) 491-0313

Application No. 10/588,392
Filed: August 03, 2006
TC Art Unit: 1639
Confirmation No.: 8285

- A. the *selecting step* - claim 2
- B. the *pretreatment* of the analyte - claim 5
- C. the *complex analyte* - claim 6
- D. the *origin* of the complex analyte - claim 18

Traverse is on the grounds that there would be no undue effort for the Examiner to search the one claim in Group II.